Osborne EM, et al. - Researchers used patients' records to investigate toxicity and outcomes in recurrent anal squamous cell carcinoma patients who received prior pelvic radiation therapy (RT), and subsequently underwent hyperfractionated accelerated re-RT to the pelvis. The observed 3-year disease-free survival and 3-year overall survival rates were 40% and 60%. They found that in patients with previously irradiated anal cancer, hyperfractionated accelerated re-RT was well tolerated. They also observed excellent rates of overall survival and freedom from local progression among patients treated with either definitive re-RT or re-RT followed by surgical resection.